Hybrid Pharma LLC, Deerfield Beach, FL

Is Hybrid Pharma LLC registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B. The list does name Hybrid Pharma, LLC in Deerfield Beach, CA, a close but not exact match shown below.

Does Hybrid Pharma LLC hold a Florida pharmacy license?

The Florida Board of Pharmacy lists 3 licenses for this name and city, as of Nov 15, 2026: PH26436 for HYBRID PHARMA LLC, DEERFIELD BEACH, status Clear, PH29374 for HYBRID PHARMA, LLC, DEERFIELD BEACH, status Clear and PH27690 for HYBRID PHARMA, LLC, DEERFIELD BEACH, status Error. The Colorado State Board of Pharmacy also lists nonresident license OSP 7236 for Hybrid Pharma, Deerfield Beach, FL, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054021434 for HYBRID PHARMA LLC, DEERFIELD BEACH, FL, status NOT RENEWED, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0003089 for HYBRID PHARMA LLC, DEERFIELD BEACH, FL, status ACTIVE (CURRENT), as of Nov 15, 2026.

Has Hybrid Pharma LLC had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Jun 7, 2022) and 1 FMD-145 letter (Jul 10, 2023) for Hybrid Pharma LLC. State board actions: record found. The Florida Board of Pharmacy’s enforcement list for pharmacy permits lists 3 actions: “Obligation(s) Satisfied” dated Apr 23, 2015, case 201309618 on license PH26436, “Administrative Complaint Filed” dated Jun 19, 2014, case 201309618 on license PH26436 and “Administrative Complaint Filed” dated Jun 19, 2014, case 201309618 on license PH26436.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Hybrid Pharma LLC
Location
Deerfield Beach, FL
Type as FDA labels it
503B
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
3
Warning letters on FDA’s actions page
1
Latest action on that page
Nov 9, 2023
FDA Data Dashboard inspections
4 inspections: 4 OAI; 3 published Form 483s
Form 483 text on this page
3 Form 483s, 27 observations
State board records
License found: PH26436, Clear; PH29374, Clear; PH27690, Error

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Hybrid Pharma LLC, a 503B facility, with 5 dated actions.

Document
Nov 9, 2023Form 483483 Issued 11/09/2023FDA copy (archived)
Jul 10, 2023FMD-145 letterFMD-145 Letter Issued 07/10/2023Not linked by FDA
Jun 7, 2022Warning letterWarning Letter (06/07/2022)FDA copy (archived)
Sep 3, 2021Form 483483 Issued 09/03/2021FDA copy (archived)
Jun 24, 2019Amended Form 483Amended 483 Issued 06/24/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Hybrid Pharma LLC, Deerfield Beach, FL (FEI number 3011319445), matched to this page by exact name, city and state. It lists 4 inspections: 4 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Nov 9, 2023Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30113194451222392
Sep 3, 2021Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30113194451150563
Jun 20, 2019Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30113194451093987
Jul 28, 2016Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3011319445983055

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 27 numbered observations in all, across 3 inspections ending Jul 28, 2016 to Sep 3, 2021. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jul 27, 2021 to Sep 3, 2021: 7 observations

Firm on the cover
Hybrid Pharma LLC, 1015 W Newport Center Dr Ste 106a, Deerfield Beach, FL 33442-7707
FEI number
3011319445
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
555 Winderley Place, Suite 200 Maitland, FL 32751
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Investigations of an unexplained discrepancy did not extend to other batches of the same drng product and other drug products that may have been associated with the specific failure or discrepancy.

Your firm does not conduct adequate investigations of unexplained events or occurrences. Specifically,

A. During the 100% visl!al inspection of Magnesium Chloride 200 mg/mL, Lot <Redacted B4>, the operator found 5 of <Redacted B4> vials containing particles. Possible sources of contamination included fibers from gowning sleeves and dust from carrying bins, resulting in a change of gowning procedures <Redacted B4>, wiping of bins, and rewashing vials. However, the investigation was not comprehensive in that it did not consider other sources of contamination such as the bulk drug, personnel contribution, or the routine movement of vials. Additionally, the investigation did not extend to other batches.

B. A complaint of particles found in 9 vials of Magnesium Chloride 200 mg/mL, Lot <Redacted B4> BUD 10/17/20, was received on 08/21/2020. You contacted recipients of Lot <Redacted B4> and relied on customer testimony to determine that other vials contained no particles. ...

Read the full 483 (PDF on fda.gov)

Observation 2

The accuracy, specificity and reproducibility of test methods have not been established.

Specifically, your method validation of ascorbic acid 500 mg/mL assay is inadequate because the validation parameters tested are not performed on the actual method used for release testing. You performed method validation studies on an HPLC method and use <Redacted B4> method for routine analysis. Comparison studies use <Redacted B4> to measure precision against HPLC results.

Observation 3

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Environmental monitoring of personnel is not always performed after aseptic processing. Specifically, microbiological fingertip samples are not collected after the processmg of small batches (of approximately less than <Redacted B4> units). For example, the following products were compounded and no fingertip or sleeve samples were collected:

A. IC/Bl2/B2/B3/Canitine/Chromium/Lucine, Lot <Redacted B4>, on 06/08/21

B. Buprenorphine HCl, Lot <Redacted B4>, on 05/07/21

Observation 4

Laboratory records do not include complete data derived from all tests, examinations and assay necessaiy to assure compliance with established specifications and standards.

Specifically, product release testing records from Januaiy 2020 to present were reviewed and do not include documentation of all data. obtained during the analysis to include, but not limited to:

A. System suitability determinations

B. Standard and sample preparations

C. Calculations performed

This is a repeat observation.from FDA-483, dated 06/24/19.

Observation 5

You did not retain reserve samples for drug products for one year after the expiration dates of the drug products.

On 08/16/21, you were unable to provide the retain sample for Magnesium Chloride, Lot <Redacted B4>, citing that it was reviewed as pali an incident/investigation (dated 03/01/21) and it was misplaced. This product was manufactured on 02/26/21, with BUD 08/26/21. In addition, you did not implement the stated procedure according to your SOP entitled Protocol for Retention Samples which states that the retain sample is discarded after the BUD.

Observation 6

Your outsourcing facility did not submit a report to FDA upon initial registration as an outsourcing facility identifying the drugs compounded during the previous six month period.

Specifically, the following products were compounded and not identified on your reports dated December 31, 2020 and/or June 30, 2021. Examples include, but are not limited to:

• Vitamin D <Redacted B4>/ml injection

• Buprenorphine 0.4 mg/ml injectable

• Alpha lipoic acid 25 mg/ml injection

• Sildenafil 110 mg capsules

• Tadalifil 10 mg troches • Dihydroepiandosterone 58 mg and pregnenolone 250 mg capsules

• Dihydroepiandosterone 12.5 mg and pregnenolone 100 mg capsules

• • Myer's cocktail: preservative-free vitamin C <Redacted B4> magnesium <Redacted B4> calcium <Redacted B4> injectable

• 7-Keto DHEA injectable

Observation 7

Bulk drug substances used by the outsourcing facility to compound drug products are not manufactured by an establishment that is registered under section 510 as required by section 503B(a)(2)(C). Specifically, the following establishments that supplied bulk substances to the outsourcing facility do not appear to be registered with the FDA:

A. CoQl0 supplied by <Redacted B4> sourced from <Redacted B4>. (~j B. Choline chloride supplied by <Redacted B4> (sourced from <Redacted B4>).

C. Benzyl bensoate supplied by <Redacted B4> (sourced from <Redacted B4>).

D. Sodium hydroxide supplied <Redacted B4> (sourced from <Redacted B4>).

[t) E. Inositol supplied by <Redacted B4> (sourced from <Redacted B4>).

F. Cyanocobalamin supplied by <Redacted B4> is sourced from <Redacted B4> is indicated to be in an "inactivated" status with FDA. Also, the cyanocobalamin COA from <Redacted B4> states "not for drug use."

Inspection May 20, 2019 to Jun 20, 2019: 11 observations

Firm on the cover
Hybrid Pharma LLC, 1015 W Newport Center Dr Ste 106A, Deerfield Beach, FL 3344 2-77 07
FEI number
3011319445
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
60 Eighth Street NE Atlanta, GA 30309
Matched to this page by
FEI number on the cover; linked from actions page
FDA document
Read the full 483 (Internet Archive copy FDA links)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.

Specifically,

1. Media fills conducted between 9/23/16 and 3/15/19 were not performed that closely simulated aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations. This is a repeat observation.

2. Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing. You have no assurance that the endotoxin level of your intrathecal drug products are safe since you do not have any endotoxin data, and your firm does not perform endotoxin testing of finished product. These drug products are made using nonsterile staiiing material.

3. HEPA filter first-air was intermittently blocked by the aseptic techniques of the sterile technician during the <Redacted B4> of Procaine 20mg/ml, lot 190524A as observed on 5/24/2019. The technician's forearm passed over the filled vials as they were filled from <Redacted B4>

4. ...

Read the full 483 (Internet Archive copy FDA links)

Observation 2

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the to produce aseptic conditions.

Specifically,

a. On 5/20/19 a brown discoloration was observed on the HEP A filter inside the ISO 5 hood located in ISO 7 Buffer Room <Redacted B4>. The same discoloration was also observed on an inoperable HEP A filter within this buffer room, located to the left of the ISO 5 hood. This filter has been inoperable for an unknown length of time.

AM ENDMENT 1

b. On 5/20/19 a brown discoloration was observed on the interior wall above the doorway within ISO 7 Buffer Room This buffer room support is the aseptic filling operations of hazardous compounds within its ISO 5 BSC hood.

C. The efficacy studies performed on 11/1/2018, and 2/4/2019 to demonstrate that <Redacted B4> disinfectant and the <Redacted B4> diinfectant and the <Redacted B4> sporicidal solution used to disinfect work surfaces, floors, walls and ceilings within your cleamooms was perfo1med using unidentified locations outside of the cleamoom. The study is not well-defined and does not represent actual use.

This is a repeat observation.

Observation 3

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically ,

1. Smoke studies are not properly conducted under dynamic conditions to assure uniform and unilateral HEPA air controls within vials from an ISO 5 zone to the <Redacted B4> ISO 5 hoods and during the transfer of ISO 5 zone to the <Redacted B4>

2. Non-viable monitoring within the ISO 7 buffer rooms is not continuously performed during routine production. A <Redacted B4> sample is collected prior to vial filling.

This is a repeat observation.

AM ENDMENT 1

Observation 4

Aseptic processing areas are deficient in that floors and ceilings are not smooth and/or hard surfaces that are easily cleanable.

Specifically ,

1. The flooring within ISO 7 Buffer Room <Redacted B4> nclude underneath the ISO 5 BSC hood contained within this room is constmcted of a vinyl tile-like surface with embedded grooves which are not easily cleanable.

2. There were several loose ceiling tiles observed above the ISO 5 hoods within your ISO 7 Buffer Rooms <Redacted B4>

Observation 5

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

Specifically,

The following deficiencies were observed in the room certification report #A2915396 dated July 30 2018

1. HEP A filter leak testing within the ISO 8 preparation room was not completed

2. HEPA filter leak testing within the ISO 7 buffer rooms were not completed

The following deficiencies were observed in the room certification report #A3083463 dated Januaiy 25 2019:

AM ENDMENT 1

Observation 6

There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.

Specifically ,

The <Redacted B4> parameters used to <Redacted B4> your HCG drug product formulations have not been validated to ensure such parameters are adequate.

Im

<Redacted B4> sterilization <Redacted B4> parameters used to <Redacted B4> the following drug products have not been validated:

Pyridoxine Hych·ochloride 1 00mg/ml <Redacted B4>

Calcium Gluconate 10% <Redacted B4> Cyanocobalamin 100mcg/ml <Redacted B4>

Observation 7

Laboratory records do not include complete data derived from all tests, examinations and assay necessary to assure compliance with established specifications and standards.

Specifically ,

1. The procedures utilized in validating the HPLC, UV Spectromet1y, and Tib'imetric methods used for potency analysis of finished chug products are not properly designed such that all data generated can be properly assessed to establish that such methods consistently meets standards of accuracy and reliability.

AM ENDMENT 1

2. Routine finished product release testing records do not include a complete record of all data

obtained during the analysis to include (but not limited to):

a. System suitability determinations b. Standards and sample preparations c. All calculations performed during the analysis

Observation 8

The written stability program for drug products does not include reliable and meaningful test methods.

Specifically,

1. There is no form al written stability program to assess all stability characteristics of finished drug products.

2. Stability studies performed to establish a six-month beyond use date for your finished products are based on trial batches and not on actual finished product lots.

This is a repeat observation

Observation 9

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

Observation 10

Employees engaged in the manufacture, processing, packing and holding of a drug product lack the training required to perform their assigned functions.

AM ENDMENT 1

Specifically,

1. There are no records documenting the training provided to the staff pharmacist in her areas of responsibility.

2. Training records are not maintained covering all responsibilities and duties assigned to technicians in the production, processing, and packaging of drug products.

3. Visual inspection training procedures and records are not documented for technicians performing visual inspections of finished product to detect defects or product contamination.

4. There is no established frequency or documentation of GMP training provided to employees.

Observation 11

The labels of your outsourcing facility's drug products are deficient.

Specifically,

The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(l0)(A). Specifically, the following information is not found on your drug product labels:

AME NDMENT 1

The statement "This is a compounded drug"

Examples of your drug product labels that do not contain this information:

Glutathione l00mg/mL

Morphine 1 0mg/mL / Bupivacaine HCl 1 0mg/mL, PF

Butt Balm 30g

Ascorbic Acid S00mg/mL

B6-Fusion l00mg/mL

This is a repeat observation.

Inspection Jul 18, 2016 to Jul 28, 2016: 9 observations

Firm on the cover
, TYPE ESTABLI SHMENT INSPECTED: Outsourcing Facility
FEI number
3011319445
FDA district office on the cover
555 Winderly Place, Suite 200; Maitland, FL 32751,
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically,

a. A review of media fills conducted between 10/2015 and 04/2016 revealed that the media fills were not representative of actual production processes in that the media fills failed to simulate a lot with the maximum number of vials. The maximum vials observed in the media fill were REDACTED (b)(4) vials. Your firm has filled the following:

i. Cyanocobalamin 1000mcg/mL, lot #01PJ13: REDACTED (b)(4) vials; ii. Cyanocobalamin 1000mcg/mL, lot #03PM01: REDACTED (b)(4) vials; iii. Methylcobalamin 1mg/mL, lot #05PM12: REDACTED (b)(4) vials; iv. Methylcobalamin 1mg/mL, lot #03PM15: REDACTED (b)(4) vials

b. Your firm has not validated your

REDACTED (b)(4). Your firm uses a REDACTED (b)(4) for the depyrogenation of glassware and amber vials REDACTED (b)(4) used in the production of sterile injectable drug products.

Observation 2

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

a. We observed a reddish, yellowish-like discoloration on the HEPA filter inside of the ISO 5 hood.

We also observed yellowish-like discoloration on the- filter located to the left of the ISO 5 Hood and yellowish-like discoloration on the HEPA filter located to the right of the ISO 5 Hood. Your firm has not conducted any investigations into the discoloration of HEP As REDACTED (b)(4) prior to the current FDA inspection.

b. Your firm has not conducted disinfectant effectiveness studies to demonstrate that the disinfectants used to clean the walls, floors, ceilings, and work surfaces in the ISO 5, 7, and 8 areas can sufficiently reduce bioburden. Your firm uses the following cleaning solutions:

i. Sterile REDACTED (b)(4)

ii. Non-Sterile REDACTED (b)(4)

iii. Non-Sterile REDACTED (b)(4)

iv. Non-Sterile REDACTED (b)(4)

v. Non-Sterile REDACTED (b)(4)

vi. Non-Sterile REDACTED (b)(4)

c. Your cleanroom design is deficient in that:

i. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Clothing of personnel engaged in the manufacturing and processing of drug products is not appropriate for the duties they perform.

Specifically, on 7/21/16, we observed the following:

a. Your operator's gowning touches the floor when donning non-sterile coveralls. We observed the upper arm of the non-sterile coveralls were inside of the ISO 5 zone during cleaning of the ISO 5 Hood.

b. Your operator donning the same gloves throughout the entire REDACTED (b)(4) cleaning process for the ISO 5 Hood, ISO 7 Buffer Room counters, and ISO 7 Buffer Room floors. The operator's gloves came in contact with the flooring of the ISO 7 Buffer Room. The gloves were not changed or sanitized prior to cleaning the contact surface of the ISO 7 Ante Room workbench, ISO 7 Ante Room floors, ISO 8 Preparation Room counters and ISO 8 Preparation Room floors. Furthermore, all surfaces are not thoroughly wiped during the REDACTED (b)(4) clean.

Observation 4

The accuracy, sensitivity, specificity and reproducibility of test methods have not been established and documented.

Specifically, your firm does not have validated methods to perform potency testing of sterile injectable products produced at your facility.

Observation 5

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically.

a. Your firm does not perform continuous pressure monitoring to ensure a cascading pressure differential is maintained throughout the cleanroom of sterile injectable products. Differential pressure readings are REDACTED (b)(4) the magnehelic gauges REDACTED (b)(4). There is no alarm system to notify the operator if a pressure excursion has occurred.

b. Your firm does not perform viable and non-viable environmental monitoring each day that sterile

drug products are produced. For example, your firm compounded the following:

i. ALPHA LIPOIC ACID 50MG/ML Lot# 07PJ15B; ii. FOLIC ACID 10MG/ML lot# 07PJ05E; iii. PHOSPHA TIDYL CHOLINE SODIUM DEOXY CHOLATE INJECTION 30mL Lot# 07PJ15; iv. ASCORBIC ACID 500mglml Lot# 03PM03B; v. B COM-50 Lot# 05PM09D; vi. GLUTATHIONE 200 mg/ml Lot# 05PM16B; vii. NANDROLONE DECAN 200mg Lot# 07PJ13B

c. Your firm does not perform gloved finger-tip testing and personnel gown testing each clay drugs purporting to be sterile are produced. For example, your firm compounded the following:

i. ALPHA LIPOIC ACID 50MG/ML Lot# 07PJ15B; ii. ...

Read the full 483 (PDF on fda.gov)

Observation 6

There is no written testing program designed to assess the stability the characteristics of drug products.

Specifically, your firm has not established a written stability program to assign beyond-use-dates greater than 60 days to your sterile injectable products.

Observation 7

Written records of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications do not always include the conclusions and follow-up.

Specifically, your procedure for handling complaints and recalls is deficient in that it does not include:

b. Criteria for determination of whether the complaint represents an unexpected adverse event or a

serious adverse event which requires reporting to the FDA.

c. Provisions to review the possible failure of the drug product to meet its specification.

d. Determination to conduct an investigation and extend to related drug if necessary.

Observation 8

Routine calibration of automatic and electronic equipment is not performed according to a written program designed to assure proper performance .

Specifically, your firm utilizes the REDACTED (b)(4) to perform in-house endotoxin testing. Per the manufacturer's instructions for use the REDACTED (b)(4) should be calibrated REDACTED (b)(4). Your records indicate the last calibration was REDACTED (b)(4).

Observation 9

The labels of your outsourcing facility's drug products are deficient.

The labels of your outsourcing facility's drug products does not include information required by sections 503B(a)(10)(A) & (B).

Specifically, the following information is not found on your drug product labeling:

The statements, "This is a compounded drug," and ''Not for resale; National drug code number; Storage and handling instructions;

Examples of drug products that do not contain this information:

ALPHA LIPOIC ACID 50 MG/ML; FOLIC ACID 10 MG/ML FOLIC ACID 1 OMG/ML

o o

In addition, the following information is not found on your drug product container labels:

• Information to facilitate adverse event reporting: www.fda.gov/medwatch and 1- 800-FDA-

Examples of drug products that do not contain this information:

THIAMINE VITAMIN B 1 INJECTION 30mL; PHOSPHATIDYL CHOLINE SODIUM DEOXYCHOLATE INJECTION 30mL

o o

Linked 483s whose text is not shown

State board of pharmacy records

The Florida Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.

LicenseType as the board gives itName on the board recordCityStatus
PH26436PharmacyHYBRID PHARMA LLCDEERFIELD BEACHClear
PH29374PharmacyHYBRID PHARMA, LLCDEERFIELD BEACHClear
PH27690PharmacyHYBRID PHARMA, LLCDEERFIELD BEACHError

Board actions

As the board words them, newest first. An entry that is a complaint, charge or notice the board filed is a charge, not a final decision; only an order or final action records the outcome.

What this covers: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. Actions in the data are dated Sep 19, 1980 to Nov 10, 2026.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 7236OSPHybrid PharmaDeerfield Beach, FLActive

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054021434LICENSED PHARMACYHYBRID PHARMA LLCDEERFIELD BEACH, FLNOT RENEWED

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0003089NONRESIDENT PHARMACYHYBRID PHARMA LLCDEERFIELD BEACH, FLACTIVE (CURRENT)

Close but not exact matches

These FDA records share a name or a former name with this pharmacy but did not meet this index’s matching rule (the same legal name with the same legal ending, in the same city and state), so they are kept on their own pages. Check them against the pharmacy you are looking for.

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 4 products naming semaglutide and tirzepatide under the labeler name “Hybrid Pharma”, matched to this pharmacy page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (4). The compounded product reports cover FDA reporting periods 2024-2 to 2026-1.

FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.

Reporting periods
26436-5608SEMAGLUTIDESEMAGLUTIDEINJECTIONSUBCUTANEOUS2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1, 2026-1Compounded drugs
26436-5635SEMAGLUTIDESEMAGLUTIDEINJECTIONSUBCUTANEOUS5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1, 2026-1Compounded drugs
26436-5622TIRZEPATIDE 10MG/MLTIRZEPATIDE 10MG/MLINJECTION, SOLUTIONSUBCUTANEOUS10 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1, 2025-2, 2026-1Compounded drugs
26436-5636TIRZEPATIDE 20MG/MLTIRZEPATIDE 20MG/MLINJECTION, SOLUTIONSUBCUTANEOUS20 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1, 2025-2, 2026-1Compounded drugs

FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.